A Study of Nasopharyngeal Carcinoma From Guangdong

NCT ID: NCT03003182

Last Updated: 2017-06-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-10

Study Completion Date

2021-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective cohort study aims to establish prognostic models, to discover toxicity associated predictors and to validate randomized trials in clinical practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasopharyngeal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

in clinical trials

No interventions assigned to this group

out of clinical trials

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histological confirmed nasopharyngeal carcinoma;
* scanned by magnetic resonance imaging from calvaria vertex to clavicles before treatment;
* pretreatment Epstein-Barr virus deoxyribonucleic acid copy number is available;
* irradiated with intensity-modulated radiotherapy;

Exclusion Criteria

* finishing anticancer therapy in two or more hospitals;
* pregnancy or lactation;
* diagnosed with other sort of cancer before or during the treatment.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sun Yat-sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fang-Yun Xie

Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fang-Yun Xie, MD

Role: CONTACT

+86-02087342618

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fang-Yun Xie, M.D.

Role: primary

+86-020-87342618

Pu-Yun OuYang, M.D.

Role: backup

+86-020-87342618

References

Explore related publications, articles, or registry entries linked to this study.

Yang SS, Wu YS, Pang YJ, Xiao SM, Zhang BY, Liu ZQ, Chen EN, Zhang X, OuYang PY, Xie FY. Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma. Eur Radiol. 2022 Jun;32(6):3649-3660. doi: 10.1007/s00330-021-08460-1. Epub 2022 Jan 6.

Reference Type DERIVED
PMID: 34989842 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-FXY-098-Dept. of RT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma
NCT03306121 ACTIVE_NOT_RECRUITING PHASE3